What type of Hepatitis C is Zepatier used to treat?
Medically reviewed by Drugs.com. Last updated on Apr 27, 2020.
Zepatier (elbasvir and grazoprevir) is a once-daily oral agent FDA-approved for HCV in February 2016.
Zepatier is given with or without ribavirin for HCV in adults with genotypes 1 (the most common, 70% of HCV patients) or 4 (the least common, ~1% of HCV patients).
Zepatier is used only if your HCV has these specific genetic markers, for which your doctor will test. In clinical trials, cure rates at 12 weeks ranged from 94 to 97 percent in genotype 1 and from 97 to 100 percent in genotype 4-infected subjects.
Common side effects with Zepatier include headache, nausea, and fatigue.
Related Medical Questions
- What are the new drugs for the treatment of hepatitis C?
- Does Epclusa cure Hep C, what is the success rate?
- Does Mavyret cure hep C (HCV)? What is the success rate?
- How much does Epclusa cost?
- How does Epclusa work in the body?
- Can you take antibiotics with Mavyret?
- What is the difference between Vosevi and Epclusa?
- Zepatier Information for Consumers
- Zepatier Information for Healthcare Professionals (includes dosage details)
- Side Effects of Zepatier (detailed)